loading page

MicroRNA-196a-3p modulates neural stem cell proliferation against cerebral ischemia/reperfusion injury by ARF4 signaling
  • +4
  • Hao Wang,
  • Yuwu Zhao,
  • Feng Wang,
  • Jiawen Yuan,
  • Gang Zhu,
  • Meng-shi Dai,
  • Jiachen Li
Hao Wang
Fudan University

Corresponding Author:[email protected]

Author Profile
Yuwu Zhao
Shanghai Jiao Tong University
Author Profile
Feng Wang
Shanghai Jiao Tong University
Author Profile
Jiawen Yuan
Shanghai Jiao Tong University
Author Profile
Gang Zhu
Shanghai Jiao Tong University
Author Profile
Meng-shi Dai
Fudan University
Author Profile
Jiachen Li
Michigan Heart Ann Arbor
Author Profile

Abstract

MicroRNA-196a-3p (miR-196a-3p) is known to increase in rat models subjected to middle cerebral artery occlusion (MCAO). In the present work, we aimed to investigate the effects of miR-196a-3p in cerebral ischemia/reperfusion (I/R) injury. Transient cerebral ischemia was induced in C57/BL6 mice subjected to MCAO. Mice were also administered miR-196a-3p antagomir by intracerebroventricular injection. MiR-196a-3p and its target ARF4 levels were quantified and cerebral infarct volume and neuronal apoptosis were evaluated. Primary neural stem cells (NSCs) were activated by oxygen–glucose deprivation/reoxygenation. NSCs were transfected with miR-196a-3p mimics, inhibitors, siARF4, or negative control using Lipofectamine 2000 reagent. ARF4, Ki-67, and Nestin expression levels were assessed using qRT-PCR and western blotting. The proliferation of NSCs was detected by CCK-8 assay and EdU staining. We found that levels of miR-196a-3p expression increased in vivo and in vitro when expression levels of its target ARF4 were decreased. We also found that miR-196a-3p aggravated cerebral I/R injury in vivo. We established that ARF4 is the target of miR-196a-3p using a dual-luciferase assay in vitro. Simultaneously, we observed that miR-196a-3p overexpression or the inhibition of ARF4 inhibited NSC proliferation. MiR-196a-3p inhibited NSC proliferation and aggravated cerebral I/R injury by targeting ARF4.